Prostate cancer
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Follow-up after curative treatment (prostatectomy, radiotherapy)
Laboratory tests
- PSA
Do not order
Long-term hormone therapy (androgen deprivation)
Fasting laboratory tests, every 3 to 6 months
- PSA
- Total testosterone
- FBC
- Serum creatinine with eGFR
- Alkaline phosphatase
- Serum calcium
- Fasting plasma glucose
- Lipid profile
- HbA1cif neededThe EAU recommends screening for diabetes with fasting plasma glucose and HbA1c at baseline and then regularly [3]. Reimbursed only in people with diabetes (monitoring of glycaemic control) [4].
- ASTif neededAbiraterone: before treatment, every 2 weeks for 3 months, then every month [9]. Other associated new-generation hormone therapies: at least once a year, more often in the first 6 months [3].
- ALTif neededAbiraterone: before treatment, every 2 weeks for 3 months, then every month [9]. Other associated new-generation hormone therapies: at least once a year, more often in the first 6 months [3].
- Serum potassiumif neededAbiraterone: every month, every 2 weeks for the first 3 months if at risk of heart failure; aim for a serum potassium ≥ 4.0 mmol/L in case of hypokalaemia [9].
- 25-hydroxyvitamin Dif neededThe EAU asks for regular monitoring of vitamin D and calcium during androgen deprivation [3]; test outside the indications covered for reimbursement [4].
Sources (9)
- Cancer - Santé Publique France. Page « Cancers » (incidence 2023 et 2018), consultée le 13/10/2026.
- Haute Autorité de santé, Institut national du cancer. Guide ALD n° 30 : Cancer de la prostate. Guide médecin, révision janvier 2012 (chapitre 4 « Suivi » et tableau 2).
- European Association of Urology (EAU), EANM, ESTRO, ESUR, ISUP, SIOG. Guidelines on Prostate Cancer, édition 2026, chapitre 7 « Follow-up ».
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 7318 (PSA total), 7320 (PSA libre), 1577 (HbA1c) et 1139 (25-OH vitamine D).
- National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management (NG131), recommandations 1.3.47 à 1.3.50 (suivi) et 1.4 (effets indésirables de l'hormonothérapie). Publiée le 9 mai 2019, dernière mise à jour le 15 décembre 2021.
- Noonan EM, Farrell TW. Primary Care of the Prostate Cancer Survivor. Am Fam Physician. 2016;93(9):764-70 (synthèse des recommandations de l'American Cancer Society de 2014).
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 8.0, juillet 2025, registre AWMF 043-022OL, chapitre 9 « Nachsorge ».
- US Preventive Services Task Force. Prostate Cancer: Screening. Final Recommendation Statement, 8 mai 2018 (recommandations C et D ; mise à jour en cours).
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit ABIRATERONE ARROW 500 mg, comprimé pelliculé (rubriques 4.2, 4.4, 4.5, 4.8), mise à jour du 29/09/2026.